{
    "clinical_study": {
        "@rank": "109137", 
        "arm_group": {
            "arm_group_label": "mirabegron group", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate safety and absorption, distribution and elimination\n      of mirabegron after oral administration to Chinese subjects."
        }, 
        "brief_title": "A Study to Evaluate Absorption, Distribution and Elimination of Mirabegron After Oral Administration to Non-elderly Healthy Chinese Subjects", 
        "completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "condition": [
            "Healthy Subjects", 
            "Plasma Concentration of Mirabegron"
        ], 
        "detailed_description": {
            "textblock": "This study is an open-label study.  The subjects will receive single administration of\n      mirabegron in a fasted condition.  After the non-dosing period, subjects will receive\n      mirabegron for 8 days."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Body weight: (male) over 50.0kg and less than 80.0kg (female) over 40.0kg and less\n             than 70.0kg\n\n          -  Body Mass Index: over 17.6 and less than 26.4 kg/m\n\n          -  Chinese subjects\n\n          -  Healthy judged by investigator or sub-investigator\n\n        Exclusion Criteria:\n\n          -  Received any investigational drugs within 120 days before the screening assessment\n\n          -  Donated 400 mL of whole blood within 90 days, 200 mL of whole blood within 30 days,\n             or blood components within 14 days before the screening assessment\n\n          -  Received medication within 7 days before hospital admission\n\n          -  A deviation from the assessment criteria of physical examinations or laboratory tests\n             at screening or upon admission\n\n          -  History of drug allergies\n\n          -  With renal, hepatic, gastrointestinal, heart, cerebrovascular or respiratory diseases\n\n          -  Received mirabegron beforehand\n\n          -  Glaucoma patient"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "44 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 10, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01747564", 
            "org_study_id": "178-CL-093"
        }, 
        "intervention": {
            "arm_group_label": "mirabegron group", 
            "description": "oral", 
            "intervention_name": "YM178 (mirabegron)", 
            "intervention_type": "Drug", 
            "other_name": "mirabegron"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Pharmacokinetics", 
            "Mirabegron", 
            "Phase 1", 
            "YM178"
        ], 
        "lastchanged_date": "December 10, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Kyushu", 
                    "country": "Japan"
                }
            }
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Study to Evaluate Pharmacokinetics of Mirabegron After Single and Multiple Oral Administration to Healthy Non-elderly Male and Female Chinese Subjects", 
        "overall_official": {
            "affiliation": "Astellas Pharma Inc", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Maximum concentration (Cmax), Area under the curve (AUC) from time 0 extrapolated to infinity (AUCinf), AUC from time of dosing to last quantifiable concentration (AUClast ), and AUC from time 0 to 24hr (AUC0-24h)", 
            "measure": "Pharmacokinetic (PK) profile for ASP015K (in plasma): Cmax, AUClast, AUCinf and AUC0-24h", 
            "safety_issue": "No", 
            "time_frame": "Day 1-5 and Day 10, 11, 14-21"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01747564"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Safety assessed by the incidence of adverse events, vital signs, lab-test and 12-lead ECGs", 
            "safety_issue": "No", 
            "time_frame": "Through day 25"
        }, 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astellas Pharma Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}